Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Partanen

Showing results (71-80 of 123) with videos related to

Pageof 13
Sort By:
British Journal of Cancer|May 1, 1992
Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
British Journal of Cancer|April 1, 1993
Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective studyP A Pasanen, M Eskelinen, K Partanen, et al.
Anticancer Research|November 1, 1995
Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancyP A Pasanen, M Eskelinen, K Partanen, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1994
Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
British Journal of Cancer|March 1, 1994
A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic scoreP A Pasanen, M Eskelinen, K Partanen, et al.
Scandinavian Journal of Gastroenterology|November 1, 1991
Diagnostic accuracy of ultrasound, computed tomography, and endoscopic retrograde cholangiopancreatography in the detection of obstructive jaundiceP A Pasanen, K Partanen, P Pikkarainen, et al.
The Italian Journal of Gastroenterology|July 1, 1992
The value of clinical assessment in the diagnosis of icterus and cholestasisP A Pasanen, P Pikkarainen, E Alhava, et al.
The Journal of Clinical Investigation|July 15, 1997
Fragile-X: neuropsychological test performance, CGG triplet repeat lengths, and hippocampal volumesP Jäkälä, T Hänninen, M Ryynänen, et al.
Neuroradiology|May 1, 1996
How should we estimate carotid stenosis using magnetic resonance angiography?R L Vanninen, H I Manninen, P K Partanen, et al.
Pageof 13

Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
British Journal of Cancer|May 1, 1992
Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
British Journal of Cancer|April 1, 1993
Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective studyP A Pasanen, M Eskelinen, K Partanen, et al.
Anticancer Research|November 1, 1995
Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancyP A Pasanen, M Eskelinen, K Partanen, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1994
Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinomaP A Pasanen, M Eskelinen, K Partanen, et al.
British Journal of Cancer|March 1, 1994
A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic scoreP A Pasanen, M Eskelinen, K Partanen, et al.
Scandinavian Journal of Gastroenterology|November 1, 1991
Diagnostic accuracy of ultrasound, computed tomography, and endoscopic retrograde cholangiopancreatography in the detection of obstructive jaundiceP A Pasanen, K Partanen, P Pikkarainen, et al.
The Italian Journal of Gastroenterology|July 1, 1992
The value of clinical assessment in the diagnosis of icterus and cholestasisP A Pasanen, P Pikkarainen, E Alhava, et al.
The Journal of Clinical Investigation|July 15, 1997
Fragile-X: neuropsychological test performance, CGG triplet repeat lengths, and hippocampal volumesP Jäkälä, T Hänninen, M Ryynänen, et al.
Neuroradiology|May 1, 1996
How should we estimate carotid stenosis using magnetic resonance angiography?R L Vanninen, H I Manninen, P K Partanen, et al.
Pageof 13